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In the intrinsic pathway of apoptosis, mitochondria play a
crucial role by releasing cytochrome c from the intermembrane
space into the cytoplasm. Cytochrome c release through Bax/
Bak-dependent channels in mitochondria has been well docu-
mented. In contrast, cyclophilin D (CypD), an important com-
ponent of permeability transition pore-dependent protein
release, remains largely undefined, and no apoptogenic proteins
that act specifically in a CypD-dependent manner have been
reported to date. Here, we describe a novel and evolutionarily
conserved protein, apoptogenic protein (Apop). Mouse Apop-1
expression induces apoptotic death by releasing cytochrome c
from mitochondria into the cytosolic space followed by activa-
tion of caspase-9 and -3. Apop-1-induced apoptosis is not
blocked by Bcl-2 or Bcl-xL, inhibitors of Bax/Bak-dependent
channels, whereas it is completely blocked by cyclosporin A, an
inhibitor of permeability transition pore. Cells lacking CypD
were resistant toApop-induced apoptosis.Moreover, inhibition
of Apop expression prevented the cell death induced by apopto-
sis-inducing substances. Our findings, thus, indicate that the
expression of Apop-1 induces apoptosis though CypD-depend-
ent pathway and that Apop-1 plays roles in cell death under
physiological conditions.
Apoptosis, which is programmed cell death, is essential in
normal development and is involved in many diseases and
pathophysiological conditions including cancer, neurodegen-
erative disorders, and atherosclerosis (1–3). There are two
major pathways for the induction of caspase-dependent apo-
ptosis; one is an extrinsic or receptor-mediated pathway which
includes Fas and tumor necrosis factor receptor, whereas the
other is an intrinsic pathway in whichmitochondria play a cru-
cial role by releasing cytochrome c from the intermembrane
space into the cytoplasm after mitochondrial outer membrane
permeabilization (4). Mitochondrial outer membrane perme-
abilization can be initiated by opening of the permeability tran-
sition (PT)2 pore, an incompletely characterized protein com-
plex presumably consisting of a voltage-dependent anion
channel, adenine nucleotide translocator (ANT), and cyclophi-
lin D (CypD) (5), although recent findings have shown that PT
pores can form in the absence of ANT (6, 7). Normally, PT
pores allowmaterials of up to 1.5 kDa to be released frommito-
chondria (8). Sustained opening of PT pores allows equilibra-
tion of ions between the matrix and cytoplasm and dissipation
of the inner membrane potential (9). However, determination
of whether PT pores are independent mediators of apoptosis
has been hampered by the lack of an apoptogen that acts solely
through them.
Mitochondrial outer membrane permeabilization is also
mediated by Bcl-2 family proteins. In this type of apoptosis,
Bcl-2 family proteins act directly on the outer mitochondrial
membrane, and PT and the inner membrane do not play major
roles, although there appear to be physical and/or functional
interactions between PT and Bcl-2 family proteins.
Regulation of cytochrome c release by both pro- and anti-
apoptotic members (10) of the Bcl-2 family of proteins is well
documented (11). The anti-apoptotic Bcl-2 family members,
such as Bcl-2, Bcl-xL and Bcl-w, share four Bcl-2 homology
(BH) domains (BH1 through BH4), although somemembers of
this group appear not to possess a BH4 domain. The pro-apo-
ptotic Bcl-2 family members can be classified into two sub-
groups based on their structure, i.e. BH3-only members and
multidomainmembers. Bad, Bid, andBim,which share only the
BH3 domain, belong to the BH3 only protein subgroup,
whereas Bax andBak, which share three BH regions (BH1, BH2,
and BH3), belong to the multidomain subgroup. The members
of these two subgroups are functionally distinct. BH3-only pro-
teins appear to function as death signal sensors (12, 13),
whereas multidomain members function as gateways for many
types of apoptotic signals, since cells lacking both Bax and Bak
are resistant to many apoptotic stimuli (14). Beside the BH
regions, many Bcl-2 family members possess a C-terminal
hydrophobic domain, which is predicted to facilitate mem-
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After being released from the intermembrane space of mito-
chondria into the cytosol, cytochrome c associates with Apaf-1
and pro-caspase-9 and forms a complex termed an apopto-
some, which leads to the activation of pro-caspase-9 (17). Sub-
sequently, the active form of caspase-9 cleaves and activates
downstream executioner caspases, such as caspase-3 (18).
Besides cytochrome c, Smac/DIABLO is also released from the
intermembrane space of mitochondria and inhibits the activity
of IAP, itself is an inhibitor of caspase-3, -7, and -9 (19–21).
Dysregulation of apoptosis results in deficient or excessive
cell death and is implicated in many human diseases. Insuffi-
cient apoptosis may be involved in carcinogenesis, whereas
excessive apoptosis is implicated in the pathogenesis of stroke,
myocardial infarction, and heart failure. For example, athero-
sclerotic plaque tends to rupture at sites of increased macro-
phages and reduced numbers of vascular smooth muscle cells
(SMC), suggesting that apoptosis of SMC, possibly induced by
activated macrophages, promotes the rupture of atheroscle-
rotic plaque (22). In the present study, we cloned a novel apop-
togenic gene from atherosclerotic SMC in culture. We named
this protein apoptogenic protein (Apop) and demonstrate that
it induces apoptosis through the CypD-dependent but Bax/
Bak-related channel-independent mechanism.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—SMC cultures were estab-
lished from plaque (P) and non-plaque (NP) areas of the
descending thoracic aorta of ApoE-deficient mice by the
explant method as described previously (23). SMC were cul-
tured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal calf serum. HeLa cells (a human cervical carci-
noma cell line) were transfected with a pUC-CAGGS vector
bearing human Bcl-2 to obtain a stable transfectant (24), which
was designated HeLa-Bcl-2. Empty vector was introduced to
obtain control HeLa cells (designated HeLa-V). HeLa cells and
transfected HeLa cells were maintained in RPMI1640 contain-
ing 10% fetal calf serum. Hepatocytes were isolated by in situ
collagenase perfusion fromwild-type and CypD-deficient mice
and cultured on collagen-coated dishes (Iwaki). CypD-deficient
mice were generated in collaboration with Lexicon Genetics
Inc, and the hepatocyteswere kindly provided byDr. Shimizu of
Osaka University. Human umbilical vein endothelial cells were
cultured in endothelial basal medium 2 (Sanko Junyaku) sup-
plemented with 2% fetal calf serum.
Differential Display—Total RNA isolated fromP andNP cul-
tures was analyzed by differential display essentially as
described by Liang and Pardee (25) with some modifications.
First-strand cDNA synthesis and PCR reactionwere performed
as previously described (23). The DNA fragment differentially
expressed by P and NP cultures was excised from the gel, re-
amplified by PCR, and cloned into a pGEM-T vector (Promega)
for sequencing.
Quantitative Real-time Reverse Transcription-PCR—RNA
was isolated from mouse tissues using ISOGEN (Nippon
Gene) according to the manufacturer’s instructions and con-
verted to cDNA by reverse transcription. A TaqMan MGB
gene expression kit was used according to the manufactur-
er’s instructions (Applied Biosystems). Quantitative PCR
was performed using real-time detection technology and
analyzed on a model 7900 sequence detector (Applied Bio-
systems). The PCR primers and fluorescent probe for
Apop-1 were as follows: forward, 5-GCCAGGATGTTGGAT-
GTGTTG-3; reverse, 5-AAGGCGGACACTGTGAGGTAA-
3; probe, 5-CAAGTGCTCTTTTGCCGAGCTGCA-3. For
Apop-2 the primers and probe were as follows: forward, 5-AGT-
CAGGCCAAAGAGCAACG-3; reverse, 5-CCTTCCCCATG-
AAGAAAGTGAT-3; probe,5-CATGTGCTTCTGGAAAT-3.
Levels of mRNA were compared after normalization to concur-
rent 18 S rRNA amplification.
Plasmid Construction—Apop-1 cDNA was cloned from
cultured SMC by reverse transcription-PCR using specific
primers and high fidelity DNA polymerase, Pyrobest
(Takara). The amplified Apop-1 cDNA was ligated with
pcDNA3.1/CT-GFP-TOPO (Invitrogen) to make Apop-1 and
green fluorescent protein (GFP) fusion protein expression vec-
tor, pcDNA3Apop-1/GFP. Apop-1 cDNA including a stop
codonwas inserted into pcDNA3.1mychis (Invitrogen) for con-
struction of the Apop-1 expression vector, pcDNA3Apop-1.
DNA encoding human truncated Bid (tBid) and Bcl-xL were
inserted into the pUC-CAGGS expression vector (26) and
pcDNA3 (Invitrogen), respectively, and used as tBid expression
vector and pcDNA3Bcl-xL. For construction of the antisense
plasmid of Apop, pcDNA3Apop-1/GFPwas digested withHin-
dIII and BamHI, and the DNA fragment including the entire
Apop coding sequence was subcloned into pcDNA3.1 in anti-
sense orientation.
Cell Treatment with Drugs and DNA Transfection—Tran-
sient transfection of expression plasmid for Apop, tBid, Bcl-xL,
or empty vector was performed using Lipofectamine and Plus
FIGURE 1. Identification of Apop protein. A, differential display comparing
expression profiles for plaque (P) and non-plaque (NP) cultures. Differential
display reaction was performed in the presence of 35S-labeled UTP, and
labeled DNA was analyzed on 6% denaturing polyacrylamide gel. Results for
three pairs of P and NP cultures from individual animals (1–3) are shown. B,
genomic structure of the mouse Apop gene. Boxes E1 through E6 indicate
exons. White boxes indicate untranslated regions, and black boxes indicate
coding regions. Alternative splicing produces two transcripts; Apop-1 is com-
posed of E1-E4, E5, and E6, and Apop-2 is composed of E1-E4 and E5. C,
expression of the Apop gene. Real-time PCR was performed using RNA iso-
lated from mouse organs. Levels of Apop-1 and Apop-2 mRNA were corrected
using 18 S rRNA as an internal control. A, aorta; B, brain; H, heart; K, kidney; Li,
liver; Lu, lung; S, spleen. Values are the mean  S.D. of three mice.
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reagents (Invitrogen) according to the manufacturer’s instruc-
tions. Antisense plasmid DNA was introduced into SMC using
a Nucleofector Basic kit for primary mammalian smooth mus-
cle cells (Amaxa Biosystems) according to the manufacturer’s
instructions. For treatment of cells with cyclosporin A (CyA),
HeLa cells were cultured and treatedwith this drug after transfec-
tion of pcDNA3Apop-1 or from 2 h before initiation of treatment
with etoposide. For endogenous Apop inhibition experiments,
SMC cultures were transfected with control (pcDNA3.1) or anti-
sense plasmid (pcDNA3AS) and incubated at 37 °C for 24 h. Cells
were then supplied with serum-free medium containing 200 M
lysophosphatidylcholine or 50 M sodium nitroprusside (SNP)
and then cultured for an additional 24 h.
Immunocytochemical Study—Cells were rinsed with PBS and
fixed with 4% paraformaldehyde in phosphate buffer (pH 7.4)
for 5 min at room temperature.
After washing with PBS and block-
ing with 1% BSA in PBS for 30 min,
the cells were incubated with anti-
HSP60 (Stressgen) or anti-cyto-
chrome c antibody (Lab Vision)
overnight at 4 °C and then washed
with PBS. Tetramethylrhodamine-
labeled anti-mouse IgG antibody
(Rockland) was added to the cells
and incubated for 1 h. For staining
of nuclei, cells were rinsed with PBS
and exposed to 10 M Hoechst
33342 (Dojindo) in PBS for 5 min.
After washing with PBS, cells were
examined under a laser scanning
confocal microscope.
Western Blot Analysis—The mito-
chondrial fraction was isolated using
digitonin, as described previously
(27). Briefly, after washing twice with
phosphate-buffered saline, the cul-
tured cells were collected and treated
with 10 M digitonin for 5 min at
37 °C. The cytosolic and organelle
fractions were separated by centrifu-
gation and lysed with radioimmune
precipitation assay buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% Nonidet
P-40, 0.5% deoxycholate, and 0.1%
SDS). Aliquots of each fraction were
subjected to Western blot analysis.
The protein extract (20 g) was
loaded onto a sodium dodecyl sulfate
polyacrylamide electrophoresis gel,
and proteins were transferred to a
polyvinylidene difluoride membrane
(Immobilon-P,Millipore). Themem-
brane was blocked with PBS contain-
ing 0.3% Tween 20 and 3% dry milk
and incubated with primary antibod-
ies (anti-cytochrome c (Lab Vision),
anti-GFP(AffinityBioReagents), anti-
-tubulin (Calbiochem), andanti-HSP60 (Stressgen)) overnight at
4 °C. The membrane was then incubated with peroxidase-conju-
gated second antibodies (Promega) for 1 h, and the immune com-
plexes were detected by a chemiluminescence method (ECL,
Amersham Biosciences).
Enzymatic Assays—Protein concentration was determined
byDC protein assay (Bio-Rad) using bovine serum albumin as a
standard. Caspase-3 and -9 activities in cells cultured for 24 h
after transfection were measured using a colorimetric assay kit
(BioVision) according to the manufacturer’s instructions.
Cell Viability Assay—To examine both adherent and float-
ing cells, cells were trypsinized (0.25%, Nacalai Tesque) and
combined with medium, centrifuged, washed, and fixed in
cold 90% ethanol for 20 min. Cells were then resuspended in
staining buffer consisting of 1 mg/ml RNase A, 20 g/
FIGURE 2. Apop homologues from Mus musculus, Rattus norvegicus, Homo sapiens, Gallus gallus, Tetra-
odon nigroviridis, C. elegans, and Drosophila melanogaster. Sequence alignment was performed using
ClustalW (48). Conserved amino acids are shown on a gray background. Positively charged amino acids are
marked with asterisks in a putative mitochondrial localization signal at the N terminus of mouse Apop. The
underlined sequence represents a predicted amphipathic -helical region. The arrow shows the predicted site of
cleavage by the mitochondrial processing protease. Tyrosine residues potentially available for phosphoryla-
tion are indicated by open triangles, and asparagines potentially available for glycosylation by closed triangles.
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ml propidium iodide (Medical
and Biological Laboratories), and
0.01% Nonidet P-40. DNA content
was determined by fluorescence-
activated cell sorting analysis on
the FL-2 channel, and gating was
set to exclude debris and cellular
aggregates. A total of 1  104 cells
were counted for each sample. In
the endogenous Apop expression
inhibition experiment, cell viabil-





ysis was performed by the unpaired t
test. Results are expressed as mean 
S.D.
RESULTS
Identification of Apop-1—In a
previous study of atherosclerotic
SMC, we compared SMC cultured
fromatherosclerotic plaque (P)with
those from non-plaque (NP) areas
of aorta of apolipoprotein E-defi-
cient mice (23). Differential display
using P and NP cell pairs from three
animals identified several tran-
scripts that differed in level of
expression. A 140-bp cDNA frag-
ment was one of these transcripts
and was more intense in P than in
NP lines in two pairs (2P  2NP,
3P  3NP) but similar in P and NP
in the third (1P  1NP) (Fig. 1A).
The nucleotide sequence of the
140-bp fragment was nearly identical
to AA546169 in the mouse EST data
base. The 5 portion of AA546169 is
identical to that of AK002873, a
cDNA clone of unknown function in
the data base. Analysis of the mouse
genome revealed that these se-
quences represent two alternatively
spliced transcripts from an Apop
locus, RIKENcDNA2810002N01, on
mouse chromosome 12. Our clone
(which we designated Apop-1) and
AA546169consistedof exons1–4, 5,
and 6, whereasAK002873 (Apop-
2) consisted of exons 1–4 and 5
(Fig. 1B). Reverse transcription-
PCR showed that both Apop-1 and
Apop-2 were expressed in all mouse
organs tested (not shown), indicating
ubiquitous expression of the Apop
FIGURE 3. Apop-1/GFP is located in mitochondria and releases cytochrome c. A, fluorescence microscopic
picture of a SMC transfected with pcDNA3Apop-1/GFP. GFP expression (left panel) and immunostaining with
Hsp60-specific antibody (middle panel) are shown. Merged picture (right panel) shows colocalization of Apop-1
and Hsp60. Scale bar, 30 m. B, localization of Apop-1/GFP and release of cytochrome c into the cytosolic space.
SMC were transfected with pcDNA3Apop-1/GFP and cultured for 24 h. Cytosolic (S) and mitochondria-contain-
ing (M) fractions were isolated by differential centrifugation and analyzed by immunoblotting using anti-
cytochrome c (Cyt c), GFP, tubulin (cytosol marker), or HSP60 (mitochondrial marker) antibodies. CTR, control
cells; ETP, etoposide-treated cells. C, release of cytochrome c from mitochondria into the cytosolic space. SMC
transfected with control vector or pcDNA3Apop-1 were immunostained with a cytochrome c-specific antibody
(anti-cytochrome c) or stained with Hoechst 33342. The cell transfected with control vector exhibits cyto-
chrome c in mitochondria and a normal nucleus, whereas the Apop-1-transfected cell exhibits cytochrome c
released into the cytosol and has an apoptotic nucleus. Scale bar, 30 m.
FIGURE 4. Expression of Apop-1 induces apoptosis. A, apoptosis induced by expression of Apop-1 or Apop-2.
Cultured SMC were transfected with control (CTR), pcDNA3Apop-1, or pcDNA3Apop-2. Microscopic photo-
graphs were taken 24 h after transfection. B, apoptosis of SMC transfected with pcDNA3Apop-1/GFP. At 24 h
after transfection, cells were photographed. Fluorescence microscopic pictures of cells stained with Hoechst
33342 exhibit condensed nuclei of Apop-1-GFP-transfected cells. C, fragmentation of DNA in cells transfected
with Apop-1-expression vector. HeLa cells were transfected with control vector or pcDNA3Apop-1 and cul-
tured for 24 h. Nuclear fragmentation was assayed by propidium iodide staining of nuclei and fluorescence-
activated cell sorter analysis. D, apoptosis of human umbilical vein endothelial cells induced by expression of
Apop-1. Cultured human umbilical vein endothelial cells were transfected with control or pcDNA3Apop-1.
Microscopic photographs were taken 24 h after transfection.
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gene. Real-time PCR revealed distinct levels of expression ofApop
gene in tissues (Fig. 1C). Apop-1 expression was highest in brain,
whereas Apop-2 was expressed at the highest level in kidney.
Structure of Apop-1—Apop-1 is composed of 194 amino
acids including 7 cysteines (Fig. 2). Apop-2 shares 160N-termi-
nal amino acids with Apop-1, whereas its C-terminal 32-amino
acid sequence is highly enriched with lysine and arginine and
exhibits no similarity with the sequence of Apop-1.
The N-terminal regions of the mouse Apop proteins have
several properties in commonwith themitochondrial targeting
sequence, including being rich in arginine, leucine, serine, and
alanine, the presence of more than two positively charged
amino acids, paucity of acidic residues, and formation of
amphiphilic -helices. Use of an algorithm for prediction of
mitochondria-targeting proteins (28) revealed a high probabil-
ity (99.96%) of mitochondrial localization of Apop-1 and pre-
dicted the presence of a mitochondrial processing peptidase
cleavage site (29). Apop is evolutionarily highly conserved, and
homologues of it can be identified in Drosophila and Caenorh-
abditis elegans (Fig. 2). However, the functions of these homol-
ogous proteins have not been defined, and no structural simi-
larities to any domains to other gene products were recognized.
Sequence analysis suggested that there are two tyrosine resi-
dues potentially available for phosphorylation and two aspar-
agines potentially available for glycosylation in the mouse
Apop-1 sequence. Of these amino acid residues, one tyrosine
and one asparagine are highly conserved across species (Fig. 2).
In addition, loose similarities to bipartite nuclear localization
signal sequence and coiled-coil sequence are present in an
Apop homologue in C. elegans. The C-terminal sequence of
Apop-2, which is enriched in arginine and lysine residues, also
suggests potential nuclear localization in addition tomitochon-
drial localization.
Mitochondrial Localization—To investigate the mitochon-
drial localization of Apop-1 predicted from the analysis
of amino acid sequence, SMC were transfected with
pcDNA3Apop-1/GFP, an expression vector of Apop-1 fused to
GFP at its C terminus. On fluorescence microscopic examina-
tion, GFP was predominantly in the cytosol and exhibited a
punctate distribution similar to that of mitochondria (Fig. 3A).
GFP was colocalized with HSP60, a mitochondrial marker, in
immunocytochemical staining with an antibody to HSP60. To
further examine the localization, cytosolic and mitochondrial
proteins were extracted from cells after transfection of
pcDNA3Apop-1/GFP (see below for cell morphology). Con-
sistent with the results of immunocytochemical observation,
GFP immunoreactivity was localized in the mitochondrial
fraction, suggesting that Apop-1 is located in mitochondria
(Fig. 3B).
Apop-1-induced Apoptotic Cell Death—To clarify the func-
tion of this novel protein, we prepared Apop-1 and Apop-2
expression vectors, pcDNA3Apop-1 and -2, and introduced
them into cultured wild-type mouse SMC. Remarkably, cells
expressing Apop-1 or Apop-2 died within 24 h after transfec-
tion (Fig. 4A). More than half of cells transfected with
pcDNA3Apop-1/GFP also died within 24 h (Fig. 4B). Cells
exhibited morphological features of apoptosis (30), i.e. cell
shrinkage and condensed/fragmented nuclei on staining with
Hoechst 33342 (Fig. 4B). Fragmentation of DNA in Apop-ex-
pressingHeLa cells was apparent on flow cytometric analysis of
propidium iodide-stained cells (Fig. 4C). Human umbilical vein
endothelial cells also died within 24 h after the transfection of
Apop-1 expression vector (Fig. 4D).
Apop-1-induced Caspase Activation—Conditioned medium
of pcDNA3Apop-1-transfected SMC failed to induce SMC
death in culture, indicating that Apop-1 does not induce the
expression of secreted apoptogenic substances such as Fas
ligand (Not shown). Apoptosis was confirmed by the inhibition
of cell death by a broad-spectrum caspase inhibitor, z-VAD-
fmk, which was partial at 50 M and complete at 100 M (Fig.
5A). This indicates that Apop-1-induced death is mediated by
the activation of caspases. Consistent with this finding, the
activity of DEVDase (caspase-3), a representative effector mol-
ecule in the apoptosis cascade, was elevated 10-fold in
pcDNA3Apop-1-transfected cells compared with that in vec-
tor-transfected control (Fig. 5B). DEVDase activationwas com-
pletely inhibited by Ac-DQTD-CHO, a casapase-3/7 inhibitor
(Fig. 5B). To examine whether activation of caspase-9, the
best characterized upstream caspase, is involved in Apop-1-
induced apoptosis, we assessed the activity of LEHDase
FIGURE 5. Apop-1 induces apoptosis of SMC through activation of
caspases. A, inhibition of Apop-1-induced apoptosis by a pan-caspase inhib-
itor, z-VAD-fmk. Cells transfected with pcDNA3Apop-1 were cultured for 24 h
in the presence of z-VAD-fmk at the indicated concentrations. Apoptosis was
measured by fluorescence-activated cell sorter. Values are the mean  S.D. of
three experiments. B, caspase-3/7 inhibitor suppresses activation of DEVDase
(caspase-3) induced by Apop-1. DEVDase activity was assayed after transfec-
tion of Apop-1 expression vector. Assays were performed with extracts of
transfected cells cultured in the presence or absence of 50 M caspase-3/7
inhibitor. Data are shown as the mean  S.D. of three experiments. C, activa-
tion of LEHDase (caspase-9) by expression of Apop-1. LEHDase activity in cell
extracts was assayed 24 h after transfection with control vector or
pcDNA3Apop-1. Values are the mean  S.D. of four experiments. D, suppres-
sion of Apop-1-induced DEVDase activation (black bars) and apoptosis (gray
bars) by a caspase-9 inhibitor. Cells were transfected with pcDNA3Apop-1
and cultured in the presence or absence of 50 M caspase-9 inhibitor. Values
are the mean  S.D. of four experiments.
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(caspase-9) and found that it also was elevated, 7-fold, in
pcDNA3Apop-1-transfected cells (Fig. 5C). Consistent with
this, a caspase-9 inhibitor, Ac-LEHD-CHO, inhibitedDEVDase
activation as well as apoptosis (Fig. 5D). These findings indicate
that Apop-1-induced apoptosis is mediated by caspase-9, an
essential component of the apoptosome, which mediates mito-
chondria-induced apoptosis.
Apop-1 Releases Cytochrome c—To examine whether cyto-
chrome c, a key molecule in the mitochondria-mediated apo-
ptotic cascade, is released frommitochondria, SMCwere trans-
fected with control vector or pcDNA3Apop-1, and cytochrome
cwas stained with a specific antibody. Immunostaining of cyto-
chrome c yielded a spotty pattern in control cells, confirming
mitochondrial localization (Fig. 3C). In contrast, SMC trans-
fected with pcDNA3Apop-1 exhibited a diffuse pattern of
staining, suggesting release of cytochrome c from the mito-
chondria into the cytosol (Fig. 3C). Western blot analysis con-
firmed the distribution of cytochrome c in both mitochon-
drial and cytosolic fractions of the transfected cells (Fig. 3B).
Translocation to the cytosol of cytochrome c was apparent
at 24 h after transfection with
pcDNA3Apop-1/GFP. Etoposide,
a chemotherapeutic drug that can
initiate the mitochondrial path-
way of apoptosis, was used as a
positive control and induced sim-
ilar translocation of cytochrome c
from mitochondria to the cytosol.
Anti-apoptotic Bcl-2 Family Mem-
bers AreUnable to Inhibit Apop-1-in-
duced Apoptosis—Apop-1 is struc-
turally distinct from the members of
theBcl-2 family in that it possesses no
BH domains, has a mitochondrial
localization signal at the N terminus,
and does not have the C-terminal
transmembranedomain,whichmany
Bcl-2 family proteins possess. To
investigate whether Apop-1-induced
apoptosis involves Bcl-2 family pro-
teins, we examined whether Bcl-2, an
anti-apoptotic Bcl-2 family member,
can inhibit apoptosis induced by
Apop-1. Both pcDNA3Apop-1 and a
vector with tBid, a pro-apoptotic
Bcl-2 family member, induced apo-
ptosis in controlHeLa cells (HeLa-V).
However, although the introduction
of tBid was unable to cause apoptosis
of cells that constitutively express
Bcl-2 (HeLa-Bcl-2), the apoptosis
induced by Apop-1 was not inhibited
by expression of Bcl-2 (Fig. 6A).
Apop-1 induced comparable degrees
of apoptosis in HeLa-V and HeLa-
Bcl-2 cells in a DNA-dose-dependent
manner, whereas tBid-induced apop-
tosis was completely eliminated in
HeLa-Bcl-2 cells (Fig. 6B). Bcl-xL is another anti-apoptotic mem-
ber of the Bcl-2 family. Consistent results were obtained when
Bcl-xL expression vector was co-transfected together with tBid or
Apop-1 expression vector. Apoptosis was not observedwhen tBid
expression vector was introduced into HeLa cells together with
Bcl-xL expression vector, whereas apoptosis was apparent when
Apop-1expressionvectorwasco-transfectedwithBcl-xL (Fig. 6C).
Quantitative analysis of apoptosis showed that co-transfection of
HeLa cells with the Bcl-xL expression vector and the tBid expres-
sion vector rescued them from apoptosis in a Bcl-xL DNA-
concentration-dependent manner. In contrast, Bcl-xL expression
had no inhibitory effect on Apop-1-induced apoptosis (Fig. 6D).
These findings indicate that Apop-1-induced apoptosis is inde-
pendent of Bcl-2 and Bcl-xL, which inhibit cytochrome c release
frommitochondria.
Inhibition of Cyclophilin D Prevents Apop-1-induced Apopto-
sis—CypD is a mitochondrial member of the cyclophilin family
(31) that catalyzes cis-trans isomerization of peptidylprolyl
bonds (32, 33). The immunosuppressive drug CyA binds spe-
cifically to cyclophilins and strongly inhibits their activity (34).
FIGURE 6. Apop-1 induces apoptosis in a Bcl-2- and Bcl-xL-independent manner. A, no inhibition by Bcl-2 of
Apop-1-induced apoptosis. HeLa-V cells and HeLa-Bcl-2 cells were transfected with 1 g each of control,
pcDNA3Apop-1, or pcDNA3tBid vectors. Although Bcl-2 expression inhibited tBid-induced apoptosis, Bcl-2
was unable to inhibit the apoptosis induced by Apop-1. Microscopic photographs show the cells 24 h after
transfection. B, apoptosis assays of the cells transfected with 0.5 and 1.0 g of DNA indicated in A. Values are the
mean  S.D. of three experiments. C, Bcl-xL is unable to inhibit apoptosis induced by Apop-1. HeLa cells were
transfected with 1.0 g of pcDNA3Apop-1 or tBid expression vector together with 0 or 1.0 g of pcDNA3Bcl-xL.
Transfection was performed using equal amounts of DNA by adjustment with pcDNA3.1. Microscopic pictures
were taken 24 h after transfection. D, apoptosis assays of the cells represented in C. HeLa cells were transfected
with 1.0 g of control, pcDNA3Apop-1, or tBid expression vector together with 0, 0.5, or 1.0 g of
pcDNA3Bcl-xL. Transfection was performed using equal amounts of DNA by adjustment with pcDNA3.1. Means
of results of three experiments are shown. Error bars show the S.D. of three experiments.
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CypD is thought to be an integral constituent of the mitochon-
drial PT pore (5), and its interaction with ANT presumably
promotes change in its conformation to open inner membrane
pores (35, 36). To examine whether Apop-1 triggers efflux of
mitochondrial proteins in CypD-dependent fashion, we exam-
ined the inhibitory effect of CyA on the release of cytochrome c
byWestern blot analysis. As shown in Fig. 7A, CyA reduced the
release of cytochrome c by Apop-1, indicating that Apop-1
induces CypD-dependent release of cytochrome c. FACScan
analysis demonstrated that the apoptosis induced by Apop-1
was significantly inhibited by CyA, which was able to reduce
apoptosis to nearly basal level (Fig. 7B). In contrast, CyAdid not
affect etoposide-induced apoptosis, which is mediated by pro-
teolytically activated Bid, a pro-apoptotic Bcl-2 family member
(37). Apop-1, thus, acts through a CypD-dependent mecha-
nism distinct from etoposide-induced apoptosis involving Bcl-
2-family members.
Cyclophilin D Deficiency Prevents Apop-1-induced Apoptosis—
To confirm CypD-related apoptosis of Apop-1, we introduced
Apop-1 into primary culture of hepatocytes of CypD-deficient
mice (38). At 24 h after transfection, numerous cells with
shrunken and apoptotic morphology was detected in wild-type
cells but not in CypD-deficient cells (Fig. 7C). In contrast, tBid
induced death of both wild-type and CypD-deficient cells. The
percentage of CypD-deficient cells that were apoptotic after
transfection with pcDNA3Apop-1 did not differ from that for
untransfected cells, whereas tBid increased apoptotic death of
CypD-deficient cells to a level comparable with that for wild-
type cells (Fig. 7D). These findings
indicate that Apop-1 induces apo-
ptosis in a CypD-dependent fashion
that is quite different from the Bax/
Bak-dependent apoptosis mediated
by tBid.
Inhibition of Apop Expression Pre-
vents Cell Death Induced by Apopto-
genic Substances—To assess the
physiological function of Apop, we
examined the effects of inhibition of
Apop gene expression using an anti-
sense plasmid, pcDNA3AS. The
inhibitory effect of the antisense plas-
mid was confirmed by reduction of
green fluorescence expressed by
the co-transfected pcDNA3Apop-1/
GFP. GFP signal was not affected by
the control plasmid (Fig. 8A). We
confirmed this result byWestern blot
analysis. The expression of Apop-1/
GFP was prevented by co-transfec-
tion of pcDNA3AS (Fig. 8B). Cells
were transfected with pcDNA3AS or
control vector and cultured in the
presence or absence of apoptosis-in-
ducing reagents. Inhibition of endog-
enous Apop gene expression using
antisense plasmid prevented the cell
death induced by lysophosphatidyl-
cholineorSNP(Fig. 8C).This finding is consistentwith the results
in Fig. 4 showing thatApop-1 induces cell death. Suppression of
Apop gene expression using antisense plasmid did not com-
pletely inhibit the death induced by SNP (Fig. 8D). This sug-
gests that SNP-induced death is partially mediated by Apop-
signaling, or Apop protein sensitize cells to death. These
findings together indicate that Apop plays roles in cell death
under physiological conditions.
DISCUSSION
We have identified a novel protein, Apop, that induces CypD-
dependent apoptosis when expressed using an expression vector.
Because Apop is highly conserved evolutionarily and lacks other
family members, it probably plays a crucial function in the physi-
ologyofcells thathas remainedunrecognized. Indeed,overexpres-
sion of Apop induces apoptotic cell death of cultured SMC, and
inhibition of Apop expression prevents cell death by apoptosis-
inducing stimuli. These findings indicate that Apop is physiologi-
cally concerned with cell death and that tight control of Apop
activity must be important for cell viability.
Recent studies suggest that mitochondria can release inter-
membrane space proteins, including cytochrome c and Smac/
DIABLO, through two different mechanisms (4, 9, 39). One
involves surgically precise permeabilization of the outer mem-
brane mediated by Bcl-2 family members, whereas the other
involves induction of the mitochondrial PT, which occurs
mainly in response to the release of Ca2 from endoplasmic
reticulum stores. It is reported that Bcl-2 family member-in-
FIGURE 7. Apop-1 induces apoptosis in a cyclophilin D-dependent manner. A, suppression of Apop-1-
induced cytochrome c release by CyA. HeLa cells were transfected with pcDNA3Apop-1. Cytosolic (S) and
mitochondria-containing (M) fractions were isolated by differential centrifugation and analyzed by immuno-
blotting using anti-cytochrome c (Cyt c, top), tubulin (middle; cytosol marker), or HSP60 (bottom; mitochondrial
marker) antibodies. CTR, cells transfected with a control vector. B, apoptosis assays of cells transfected with
pcDNA3Apop-1 or treated with etoposide (ETP). CyA inhibited the apoptosis induced by Apop-1 but not that
induced by etoposide. HeLa cells were transfected with pcDNA3Apop-1 or cultured in the presence of etopo-
side with or without treatment with CyA. Apoptosis was assayed 24 h after transfection or 48 h after the start of
etoposide treatment. Values are the mean  S.D. from four experiments. Asterisks denote p  0.001 versus
Apop-1-introduced cells (second bar from the left). C, CypD deficiency prevents apoptosis induced by Apop-1.
Hepatocytes from wild-type (WT) mice and CypD-deficient mice (KO) were transfected with pcDNA3.1 (control),
pcDNA3Apop-1, or pcDNA3tBid. Microscopic pictures show the cells 24 h after transfection. D, apoptosis assays
of the cells represented in C. Apoptosis assay was performed 24 h after transfection, and values are the mean 
S.D. of four experiments. Asterisks denote p  0.001 versus wild-type cells.
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duced cell death does not depend on CypD and that CypD and
mitochondrial PTs are required for mediation of Ca2- and
oxidative damage-induced cell death (40). These results are
consistent with our finding that Apop-1-induced CypD-
dependent cell death is not inhibited by anti-apoptotic Bcl-2
family members and demonstrate that Bcl-2 family-mediated
cell death is a pathway distinct from that dependent on CypD.
CypD is a component of PT pores together with voltage-de-
pendent anion channel and ANT, although the physiological
role of ANT in these pores is still debated (6, 7). It appears that
Apop-1 acts on PT pores and induces apoptosis. The amino
acid sequence of Apop-1 revealed that it is a soluble protein
without transmembrane domains, suggesting that Apop-1 is
located in the matrix or in the intermembrane space of mito-
chondria. The mechanism by which Apop induces CypD-de-
pendent release of cytochrome c requires further investigation.
We found thatApop-1-inducedapoptosiswasnotpreventedby
anti-apoptotic Bcl-2 family members, whereas it was inhibited by
CyA or CypD deficiency.We also showed that Apop-1 is a CypD-
dependent apoptogenic protein that does not act on Bax/Bak-de-
pendent channels. Unlike Bcl-2 family members, Apop-1 pos-
sesses neither BH domains nor a C-terminal transmembrane
domain. Instead, it possesses a mitochondrial localization signal
(mitochondrial targeting sequence) at the N terminus. Apop-1 is,
thus, a novel pro-apoptotic protein that is not considered amem-
berof theBcl-2 family. It is atpresent theonlyproteinknowntoact
specifically in a CypD-dependent fashion and may be useful for
study of the CypD-mediated apoptotic pathway.
Notably, although transcripts for both Apop-1 and Apop-2
are present in various tissues of mice, the significance of alter-
native splicing of Apop is yet to be determined. The C-terminal
34-amino acid sequence of Apop-1 differs from the C terminus
of Apop-2 and lacks the positively charged amino acids that are
highly conserved among theApophomologues present in other
species. A data base search failed to identify any EST sequences
that share homology with the 34-amino acid sequence. Thus,
although it is apoptosis-inducing, Apop-1 may not have all of
the normal functions of Apop. Nevertheless, although we have
not demonstrated CypD-dependent apoptosis by Apop-2, it is
very likely that Apop-2 induces apoptosis by the same mecha-
nism as Apop-1 and that CypD-dependent apoptosis is medi-
ated by the first 160 amino acids of Apop. The importance of
the N-terminal 160-amino acid sequence for the function of
Apopmay be consistent with our finding that the fusion of GFP
at the C terminus of Apop-1 does not substantially affect the
apoptogenic activity of Apop-1.
We also note that Apop-1 was originally isolated because
expression of it was higher in atherosclerotic plaque-derived
SMC than in non-plaque-derived SMC by differential display.
Apoptotic death of SMC is an important process during the
development of atherosclerotic plaque.Decrease in SMCdue to
apoptosis could also contribute to the formation of vulnerable
plaque, which is prone to rupture and causes cardiovascular
events (41). Indeed, there is increased SMC apoptosis in symp-
tomatic plaque (35, 42, 43) in patients presenting with unstable
angina compared with patients with stable angina, and apopto-
tic macrophages are co-localized with sites of plaque rupture
(44). Direct evidence of a causal relationship between plaque
rupture and apoptosis in an animal model was obtained with
the finding that induction of SMC apoptosis in fibrous cap of
mouse lesions induces plaque rupture and thrombosis of
plaque (45). Several studies have examined the effects on exper-
imental atherosclerosis of CyA and FK506, which are immuno-
suppressive drugs used for transplant rejection. The results
obtained are somewhat contradictory; CyA accelerated ather-
osclerosis in hyperlipidemic mice (46), whereas a recent study
found that low dose FK506 blocked atherosclerosis and stabi-
lized plaque in ApoE-deficientmice (47). Because they are both
immunosuppressive drugs, the mechanisms by which they
exert effects on atherosclerosis would be more complex than
merely by affecting apoptosis. Nevertheless, we showed in the
present study that Apop-1 expression induces apoptosis of
SMC and that CyA prevents apoptosis induced by Apop-1. It
will, therefore, be important to assess the level of expression of
FIGURE 8. Inhibition of Apop expression protects cells from apoptosis-
inducing reagents. A, antisense plasmid inhibits Apop expression. Antisense
plasmid, pcDNA3AS, or control vector, pcDNA3.1, was introduced into cul-
tured SMC together with pcDNA3Apop-1/GFP. Fluorescence microscopic
photographs were taken 24 h after their introduction. B, Western blot analysis
reveals prevention of Apop expression. SMC were transfected with
pcDNA3AS (AS) or pcDNA3.1 (CTR) together with pcDNA3Apop-1/GFP. Cell
lysates were prepared after 24 h of incubation, and Apop-1/GFP expression
was determined by Western blot analysis. Tubulin expression shows uniform-
ity of protein loading. C, inhibition of Apop expression prevents cell death
induced by lysophosphatidylcholine (LPC) and SNP. SMC cultures were trans-
fected with control (pcDNA3.1) or antisense plasmid (pcDNA3AS) and then
treated with lysophosphatidylcholine or SNP. Cell viability was assessed by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. D,
apoptosis induced by SNP is partially inhibited by antisense plasmid intro-
duction. Assays were performed as in C. Values are the mean  S.D. for six
experiments each. Asterisks denote p  0.001 versus vector-introduced con-
trols. The paragraph symbol (¶) denotes p  0.01 as compared with
pcDNA3AS transfected control.
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Apop in atherosclerotic plaque in vivo and to determine the
significance of the Apop proteins in atherosclerosis and other
pathophysiological conditions.
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